HHS to review nutrients, test for heavy metals in infant formula
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Mar 18 2025
0mins
Source: SeekingAlpha
Operation Stork Speed Launch: The HHS has initiated "Operation Stork Speed" to evaluate nutrients in infant formulas and test for heavy metals and contaminants, while also urging formula manufacturers to improve product transparency and address health research gaps.
Industry Meetings and Concerns: HHS Secretary Robert F. Kennedy Jr. is meeting with infant formula executives amid ongoing lawsuits against companies like Abbott and Reckitt Benckiser regarding risks associated with their products, particularly concerning the intestinal disease necrotizing enterocolitis.
Analyst Views on ABT
Wall Street analysts forecast ABT stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ABT is 148.11 USD with a low forecast of 136.00 USD and a high forecast of 169.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
19 Analyst Rating
17 Buy
2 Hold
0 Sell
Strong Buy
Current: 108.610
Low
136.00
Averages
148.11
High
169.00
Current: 108.610
Low
136.00
Averages
148.11
High
169.00
About ABT
Abbott Laboratories is a global healthcare company. The Company’s principal business is the discovery, development, manufacture, and sale of a broad and diversified line of healthcare products. Its segments include Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. Established Pharmaceutical Products segment is engaged in the international sales of a broad line of branded generic pharmaceutical products. Diagnostic Products segment is involved in the worldwide sales of diagnostic systems and tests for blood banks, hospitals, commercial laboratories and alternate-care testing sites. Nutritional Products segment is engaged in the worldwide sales of a broad line of adult and pediatric nutritional products. Medical Devices segment is involved in the worldwide sales of rhythm management, electrophysiology, heart failure, vascular, structural heart, neuromodulation and diabetes care products. It serves people in more than 160 countries.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
